LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients

Were pleased to announce our plans for developing LB-001 in pediatric patients with MMA.